The Cancer Program at Cincinnati Children’s Hospital Medical Center is home to a world-class multidisciplinary team of medical specialists who care for children and adolescents with cancer and related conditions. Experienced clinicians and researchers partner to develop and deliver innovative therapies for high-risk and relapsing cancer, including promising new treatments available only through clinical studies.

Full Spectrum of Conditions Treated
Cutting-edge clinical cancer programs and research initiatives include innovative gene therapy and stem cell transplantation programs for high-risk brain tumors; new therapies for children with relapsed and high-risk cancers, including a nationally recognized developmental therapeutics program and a blood and marrow transplantation program; and unique comprehensive multidisciplinary care and research programs for children with Fanconi anemia, Down syndrome and neurofibromatosis. Our focused subspecialty cancer teams offer comprehensive consultation and care for children and adolescents with:

- High-risk and relapsed leukemia and lymphoma
- Brain tumors
- Neuroblastoma
- Liver and kidney tumors
- Retinoblastomas
- Musculoskeletal tumors
- Neurofibromatosis and tuberous sclerosis

Program Highlights
- International leader in cancer care, the development of new cancer therapies, and in blood and marrow transplantation
- More than 50 cancer clinicians and researchers and more than 400 support personnel
- More than 75 research grants from the National Institutes of Health (NIH) and other national cancer research funding agencies, totaling nearly $9 million in direct support
- Accredited by the Foundation for the Accreditation of Cellular Therapy and by the American College of Surgeons, and recognized by the National Marrow Donor Program for best performance in donor search and selection, nationally
Access to New Therapies Through Clinical Studies

Cincinnati Children’s is one of the largest research centers for pediatric cancers in the United States. Our faculty lead clinical study efforts in major U.S. pediatric cancer research consortia, including:

- Children’s Oncology Group (COG)
- National Cancer Institute Pediatric Phase I Consortium
- Pediatric Blood and Marrow Transplant Consortium (PBMT)
- New Approaches to Neuroblastoma Therapy Consortium (NANT)
- Department of Defense Neurofibromatosis Consortium
- Collaborative Ependymoma Research Network (CERN)
- Pediatric Brain Tumor Consortium (PBTC)

Currently, we have more than 155 research studies following more than 2,800 patients, including 27 Phase I studies.

Internationally Recognized Leadership

**John Perentesis, MD, FAAP**, Director of the Division of Oncology and an expert on high-risk and relapsed leukemias and cancers, serves on the National Cancer Institute’s Investigational Drug Steering Committee and Pediatric Phase I Consortium Steering Committee. He is also a member of the Executive Committee of the Children’s Oncology Group (COG) and chair of the COG’s Myeloid Leukemia Relapse Committee.

**Stella Davies, MBBS, PhD, MRCP**, Director of the Division of Bone Marrow Transplantation and Immune Deficiency, is an internationally recognized authority on blood and marrow transplantation and serves as Chair of Pediatric Oncology for the Center for International Bone Marrow Transplant Research.

**Alexandra (Lisa) H. Filipovich, MD**, Director of the Immunodeficiency and Histiocytosis Program and an expert in cancers with immunodeficiency and histiocytic disorders, is the immediate past president of the Histiocyte Society, an international organization of researchers dedicated to research and treatment of histiocytic disorders, and has served as chair of the International Bone Marrow Transplant Registry.

**Maryam Fouladi, MD, MSc**, Medical Director of the Neuro-Oncology Program, is a nationally-recognized expert in the care of children with brain tumors and in new anticancer drug development and is chair of the Pediatric Brain Tumor Consortium.

**Denise Adams, MD**, Medical Director of the Comprehensive Hemangioma and Vascular Malformation Clinic, is a nationally recognized expert on vascular malformations and a pioneer in research on and treatment of these conditions.

For urgent issues, or to speak with the specialist on call 24/7, call the Physician Priority Link at 1-888-987-7997. For international inquiries, call +1-513-636-3100 or email international@cchmc.org.